Clinical trial
Safety and Efficiency Study of CD19-PD1-CART Cell in Relapsed/Refractory B Cell Lymphoma
NCT04163302 is registered in ClinicalTrials.gov with Chinese PLA General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Safety and Efficiency Study of CD19-PD1-CART Cell in Relapsed/Refractory B Cell Lymphoma
- Lead sponsor
- Chinese PLA General Hospital
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- July 7, 2019
- Completion date
- July 1, 2022
- Enrollment
- 30 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.